Cronos Group Inc.
Health
Performance
5.8
Risk
Sell
Buy
Curious about the Scores? Learn more.

Cronos Group Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

23.07.2026
Losing steam. Not trending your way right now.
01.07.2026
On shaky ground. Struggling to find a clear direction.
01.07.2026
Health turning shaky. Something under the hood’s off.
12.05.2026
Signs of control returning. Still shaky, but not chaos.
CRON
Cronos Group Inc.
2.78
-0.71%
5.8
Sell
Buy
Cronos Group Inc.

Cronos Group Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Cronos Group Inc. do? Business model and key facts

Get the full picture of Cronos Group Inc.: what it builds, where it operates, and how it makes money.

Cronos Group Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 610

Cronos Group Inc. is a company primarily focused on cannabinoids. In the United States, it develops, promotes, and supplies hemp-derived wellness and beauty products under the Lord Jones and Happy Dance brands, reaching consumers through online sales, traditional retail outlets, and partnerships within the hospitality sector. Beyond hemp, the company also engages in the cultivation, production, and commercialization of cannabis and its related extracts for both therapeutic and recreational consumption. Its cannabis offerings encompass dried flower, pre-rolled joints, edibles, concentrates, and various extracts, which are distributed via wholesale channels and directly to clients. The wellness segment operates under the PEACE NATURALS platform, while its adult-use products are marketed through the Spinach brand. Additionally, Cronos exports dried cannabis and cannabis oils to international markets such as Germany, Israel, and Australia. Founded in 2012, the company's headquarters are located in Toronto, Canada.

shop
Company facts
Michael Ryan Gorenstein
CEO
610
Employees worldwide
shop
Performance
29.91%
Last 12 months
-61.55%
Last 5 years
shop
Growth
$149.15M
Revenue year
$-2,929,000
Net income
shop
Valuation
$1.04B
Market Cap
-104.44
Price/Earnings Ratio

Stocks related to Cronos Group Inc.

Selected based on industry alignment and relative market positioning.

COLL
Collegium Pharmaceutical, Inc.
34.72
-3.15%
4.6
Sell
Buy
Collegium Pharmaceutical, Inc.
ALVO
Alvotech
3.19
-9.38%
6.8
Sell
Buy
Alvotech
PAHC
Phibro Animal Health Corporation
33.81
-0.15%
8.5
Sell
Buy
Phibro Animal Health Corporation
PCRX
Pacira BioSciences, Inc.
25.59
-0.74%
3.2
Sell
Buy
Pacira BioSciences, Inc.
GUD.TO
Knight Therapeutics Inc.
9.68
-2.91%
3.1
Sell
Buy
Knight Therapeutics Inc.

Events and news impacting Cronos Group Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Cronos Group Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.